ArticlePloS one2013
Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 60 citations in OpenAlex.
- Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation.Clinical and experimental medicine · 2025Review
- Age-dependent changes in phagocytic activity: in vivo response of mouse pulmonary antigen presenting cells to direct lung delivery of charged PEGDA nanoparticles.Journal of nanobiotechnology · 2024Article
- An evolving perspective on novel modified release drug delivery systems for inhalational therapy.Expert opinion on drug delivery · 2023Review
- Aluminum-based metal-organic framework nanoparticles as pulmonary vaccine adjuvants.Journal of nanobiotechnology · 2023Article
- Targeting of phagolysosomes containing conidia of the fungus Aspergillus fumigatus with polymeric particles.Applied microbiology and biotechnology · 2023Article
- Nebulization of Model Hydrogel Nanoparticles to Macrophages at the Air-Liquid Interface.Frontiers in chemical engineering · 2023Article
- Nanoparticle Internalization Promotes the Survival of Primary Macrophages.Advanced nanobiomed research · 2022Article
- Hydrogel nanoparticle degradation influences the activation and survival of primary macrophages.Journal of materials chemistry. B · 2021Article
- Evaluating UiO-66 Metal-Organic Framework Nanoparticles as Acid-Sensitive Carriers for Pulmonary Drug Delivery Applications.ACS applied materials & interfaces · 2020Article
- Pulmonary Delivery of Nanoparticle-Bound Toll-like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer.ACS nano · 2020Article
- Degradation Profiles of Poly(ethylene glycol) diacrylate (PEGDA)-based hydrogel nanoparticles.Polymer chemistry · 2020Article
- In vivo Studies on Pharmacokinetics, Toxicity and Immunogenicity of Polyelectrolyte Nanocapsules Functionalized with Two Different Polymers: Poly-L-Glutamic Acid or PEG.International journal of nanomedicine · 2019Article
- Pulmonary Exposure to Magnéli Phase Titanium Suboxides Results in Significant Macrophage Abnormalities and Decreased Lung Function.Frontiers in immunology · 2019Article
- Antiviral efficacy of nanoparticulate vacuolar ATPase inhibitors against influenza virus infection.International journal of nanomedicine · 2018Article
- TIPS pentacene loaded PEO-PDLLA core-shell nanoparticles have similar cellular uptake dynamics in M1 and M2 macrophages and in corresponding in vivo microenvironments.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
- Polymeric nanoparticles in development for treatment of pulmonary infectious diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016Review
- Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.Molecular pharmaceutics · 2016Article
- Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells.Nanomedicine : nanotechnology, biology, and medicine · 2016Article
- Article
- Towards programming immune tolerance through geometric manipulation of phosphatidylserine.Biomaterials · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Nanomedicine has the potential to transform clinical care in the 21(st) century. However, a precise understanding of how nanomaterial design parameters such as size, shape and composition affect the mammalian immune system is a prerequisite for the realization of nanomedicine's translational promise. Herein, we make use of the recently developed Particle Replication in Non-wetting Template (PRINT) fabrication process to precisely fabricate particles across and the nano- and micro-scale with defined shapes and compositions to address the role of particle design parameters on the murine innate immune response in both in vitro and in vivo settings. We find that particles composed of either the biodegradable polymer poly(lactic-co-glycolic acid) (PLGA) or the biocompatible polymer polyethylene glycol (PEG) do not cause release of pro-inflammatory cytokines nor inflammasome activation in bone marrow-derived macrophages. When instilled into the lungs of mice, particle composition and size can augment the number and type of innate immune cells recruited to the lungs without triggering inflammatory responses as assayed by cytokine release and histopathology. Smaller particles (80×320 nm) are more readily taken up in vivo by monocytes and macrophages than larger particles (6 µm diameter), yet particles of all tested sizes remained in the lungs for up to 7 days without clearance or triggering of host immunity. These results suggest rational design of nanoparticle physical parameters can be used for sustained and localized delivery of therapeutics to the lungs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.